EA200701802A1 - Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2 - Google Patents

Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2

Info

Publication number
EA200701802A1
EA200701802A1 EA200701802A EA200701802A EA200701802A1 EA 200701802 A1 EA200701802 A1 EA 200701802A1 EA 200701802 A EA200701802 A EA 200701802A EA 200701802 A EA200701802 A EA 200701802A EA 200701802 A1 EA200701802 A1 EA 200701802A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vegf
inhibitors
imidazo
pyridine
connections
Prior art date
Application number
EA200701802A
Other languages
English (en)
Other versions
EA011691B1 (ru
Inventor
Дэвид Энтони Барда
Тимоти Пол Беркхолдер
Джошуа Райан Клэйтон
Янь Хао
Перри Кларк Хит
Джеймс Роберт Генри
Джон Монте Нобелок
Дэвид Мендел
Джонатан Александер Маклин
Дэвид Майкл Ремик
Марк Эдвард Ремпала
Чжао-Цин Ван
Ивонне Йи Май Йип
Боюй Чжун
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200701802A1 publication Critical patent/EA200701802A1/ru
Publication of EA011691B1 publication Critical patent/EA011691B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение предлагает соединения, которые являются ингибиторами VEGF-R2, формулыи их применение.
EA200701802A 2005-02-24 2006-02-23 ИМИДАЗО(1,2-a)ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ VEGF-R2 EA011691B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (2)

Publication Number Publication Date
EA200701802A1 true EA200701802A1 (ru) 2008-02-28
EA011691B1 EA011691B1 (ru) 2009-04-28

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701802A EA011691B1 (ru) 2005-02-24 2006-02-23 ИМИДАЗО(1,2-a)ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ VEGF-R2

Country Status (34)

Country Link
US (1) US7666879B2 (ru)
EP (1) EP1904494B1 (ru)
JP (1) JP5055136B2 (ru)
KR (1) KR100904938B1 (ru)
CN (1) CN101128461B (ru)
AR (1) AR056186A1 (ru)
AT (1) ATE490254T1 (ru)
AU (1) AU2006216710B2 (ru)
BR (1) BRPI0609047A2 (ru)
CA (1) CA2599124C (ru)
CR (1) CR9331A (ru)
CY (1) CY1111154T1 (ru)
DE (1) DE602006018615D1 (ru)
DK (1) DK1904494T3 (ru)
DO (1) DOP2006000051A (ru)
EA (1) EA011691B1 (ru)
ES (1) ES2354716T3 (ru)
HK (1) HK1118284A1 (ru)
HR (1) HRP20100677T1 (ru)
IL (1) IL184717A (ru)
MA (1) MA29433B1 (ru)
MX (1) MX2007010326A (ru)
NO (1) NO20074666L (ru)
NZ (2) NZ560402A (ru)
PE (1) PE20061098A1 (ru)
PL (1) PL1904494T3 (ru)
PT (1) PT1904494E (ru)
RS (1) RS51590B (ru)
SI (1) SI1904494T1 (ru)
TN (1) TNSN07323A1 (ru)
TW (1) TW200640924A (ru)
UA (1) UA91535C2 (ru)
WO (1) WO2006091671A1 (ru)
ZA (1) ZA200707136B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5442448B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
EP2121687B1 (en) 2006-12-22 2015-10-14 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
ES2393430T3 (es) * 2007-10-17 2012-12-21 Novartis Ag Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK
GB0810902D0 (en) * 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
ES2660051T3 (es) 2012-09-28 2018-03-20 Vanderbilt University Compuestos heterocíclicos condensados como inhibidores selectivos de BMP
MX2015006513A (es) * 2012-11-29 2015-08-14 Hoffmann La Roche Derivados de imidazopiridina.
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN106029660B (zh) 2013-12-16 2019-11-15 阿萨纳生物科技有限责任公司 P2x3和/或p2x2/3化合物和方法
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
ES2742192T3 (es) * 2014-06-03 2020-02-13 Univ Arizona Derivados del bencimidazol
AU2015291522B2 (en) 2014-07-17 2018-12-06 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2018526452A (ja) 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Ｄｙｒｋ１ａの小分子抑制剤およびその使用
US10160747B2 (en) * 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
EP3917935A4 (en) * 2019-01-30 2022-11-16 Avista Pharma Solutions, Inc. SYNTHESIS PROCESS AND NEW INTERMEDIATES
US11459331B2 (en) 2019-01-30 2022-10-04 Avista Pharma Solutions, Inc. Chemical compounds
CN111574521A (zh) * 2019-02-18 2020-08-25 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
WO2020263187A1 (en) * 2019-06-25 2020-12-30 Sinopsee Therapeutics Compounds for treatment of eye disorders
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6492529B1 (en) * 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
EP1408950B1 (en) 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2005530745A (ja) * 2002-05-02 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7262199B2 (en) * 2002-12-11 2007-08-28 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2005016928A1 (ja) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体

Also Published As

Publication number Publication date
SI1904494T1 (sl) 2011-02-28
CR9331A (es) 2008-03-31
HK1118284A1 (en) 2009-02-06
JP5055136B2 (ja) 2012-10-24
JP2008531574A (ja) 2008-08-14
HRP20100677T1 (hr) 2011-01-31
MX2007010326A (es) 2007-10-16
CA2599124A1 (en) 2006-08-31
KR20070099029A (ko) 2007-10-08
WO2006091671A1 (en) 2006-08-31
IL184717A0 (en) 2007-12-03
ES2354716T3 (es) 2011-03-17
NZ584753A (en) 2011-06-30
EP1904494A1 (en) 2008-04-02
DOP2006000051A (es) 2006-08-31
NO20074666L (no) 2007-11-09
DE602006018615D1 (de) 2011-01-13
CA2599124C (en) 2013-08-06
CY1111154T1 (el) 2015-06-11
IL184717A (en) 2011-11-30
US20090227622A1 (en) 2009-09-10
MA29433B1 (fr) 2008-05-02
UA91535C2 (en) 2010-08-10
US7666879B2 (en) 2010-02-23
AR056186A1 (es) 2007-09-26
DK1904494T3 (da) 2011-02-21
RS51590B (en) 2011-08-31
NZ560402A (en) 2010-06-25
EA011691B1 (ru) 2009-04-28
AU2006216710B2 (en) 2011-08-11
BRPI0609047A2 (pt) 2010-11-16
EP1904494B1 (en) 2010-12-01
ZA200707136B (en) 2008-11-26
PE20061098A1 (es) 2006-10-20
TNSN07323A1 (en) 2008-12-31
CN101128461B (zh) 2010-12-22
AU2006216710A1 (en) 2006-08-31
TW200640924A (en) 2006-12-01
ATE490254T1 (de) 2010-12-15
PL1904494T3 (pl) 2011-04-29
CN101128461A (zh) 2008-02-20
KR100904938B1 (ko) 2009-06-29
PT1904494E (pt) 2010-12-23

Similar Documents

Publication Publication Date Title
EA200701802A1 (ru) Имидазо(1,2-а)пиридиновые соединения в качестве ингибиторов vegf-r2
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
MX2008001538A (es) Aril piridinas y metodos para su uso.
HRP20080664A2 (en) Substituted pyridine herbicides
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
SE0301372D0 (sv) Novel compounds
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
EA200702071A1 (ru) Новые соединения
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
EA201000258A1 (ru) Новые гербициды
NO20093040L (no) Kinolinderivater som CRTH2 reseptorligander
DK1742950T3 (da) Pyrazolo-[4,3-D]-pyrimidiner
EA200601589A1 (ru) Производные 7h-8,9-дигидропирано-(2,3-c)имидазо(1,2a)пиридина и их применение в качестве ингибиторов секреции кислоты желудочного сока

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ TJ RU